Advanced search
Start date
Betweenand

Systematic collection and consistency of the unified database from the Pulmonary Oncology Translational Group (GTOP)

Grant number: 22/00479-3
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): June 01, 2022
Effective date (End): May 31, 2023
Field of knowledge:Interdisciplinary Subjects
Principal researcher:Letícia Ferro Leal
Grantee:Alice Ornellas Ferrari
Home Institution: Hospital do Câncer de Barretos. Fundação Pio XII (FP). Barretos , SP, Brazil

Abstract

Lung cancer is marked by worrying epidemiological data, such as high incidence, low survival, and late diagnosis. At the Hospital de Amor (HA), 540 cases were diagnosed in 2019, 70% with metastatic disease. Studies involving the collection of consistent and secure data are relevant to improving the clinical status of patients. For this reason, the Translational Group on Pulmonary Oncology (GTOP) aims to unify data from patients treated at HA in a single database on the REDCap platform to generate consistent data on the profile of patients and facilitate other research projects in different areas. Objectives: to carry out a survey of sociodemographic, clinical, pathological, and molecular data of patients with lung cancer and improve the GTOP database. Methodology: the information contained in the electronic and physical records of 2000 HA patients will be collected and included in the GTOP database stored in the REDCap platform. Forms containing variables common to all potential projects will be filled out ("general information", "pathology", "clinical data and treatment", "molecular diagnosis" and "follow up"). After the data collection is completed, the database consistency will be carried out - through "data quality" and manual curation. At the end, descriptive statistics of all cases will be performed. Expected results: for a sample of 2,000 patients, an average age of around 60 years is expected, with most patients being male. About 80% of patients who are active smokers or ex-smokers are expected, most cases present stage IV at diagnosis, and about 20% of all cases with curative intent treatment. It is estimated that about 20% of patients with mutations in the EGFR gene and those diagnosed from 2011 onwards have been treated with TKi.(AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Please report errors in scientific publications list by writing to: cdi@fapesp.br.